The burgeoning field of psychedelic-assisted therapy just saw a significant capital injection, as Beond Ibogaine Inc., a company focused on wellness and healing through its unique treatment approach, announced it has closed a $13.0M seed funding round. This early-stage capital infusion signals investor interest in solutions for mental health and personal growth.
Beond Ibogaine Inc. specifically offers psychedelic-assisted treatments designed to address a range of conditions. These include depression, anxiety, trauma, and addiction, alongside programs aimed at life optimization.
